Zobrazeno 1 - 10
of 21
pro vyhledávání: '"MESH: Metabolic Clearance Rate"'
Publikováno v:
Pharmacy Practice
Pharmacy Practice, Vol 17, Iss 1, p 1304 (2019)
Pharmacy Practice (Granada) v.17 n.1 2019
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Pharmacy Practice (Granada), Volume: 17, Issue: 1, Article number: 1304, Published: 11 NOV 2019
Pharmacy Practice, Vol 17, Iss 1, p 1304 (2019)
Pharmacy Practice (Granada) v.17 n.1 2019
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Pharmacy Practice (Granada), Volume: 17, Issue: 1, Article number: 1304, Published: 11 NOV 2019
Background: Inappropriate medication dosing in patients with chronic kidney disease can cause toxicity or ineffective therapy. Patients are at a high risk of developing related adverse events caused by the altered effect of drugs in conjunction with
Autor:
Xavier Pivot, Bruno Chauffert, Jean-Pierre Kantelip, Emmanuel Guardiola, Vincent Jullien, Bruno Heyd, Bernard Royer
Publikováno v:
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 2009, 48 (3), pp.169-80. ⟨10.2165/00003088-200948030-00003⟩
Clinical Pharmacokinetics, Springer Verlag, 2009, 48 (3), pp.169-80. ⟨10.2165/00003088-200948030-00003⟩
Clinical Pharmacokinetics, Springer Verlag, 2009, 48 (3), pp.169-80. 〈10.2165/00003088-200948030-00003〉
Clinical Pharmacokinetics, 2009, 48 (3), pp.169-80. ⟨10.2165/00003088-200948030-00003⟩
Clinical Pharmacokinetics, Springer Verlag, 2009, 48 (3), pp.169-80. ⟨10.2165/00003088-200948030-00003⟩
Clinical Pharmacokinetics, Springer Verlag, 2009, 48 (3), pp.169-80. 〈10.2165/00003088-200948030-00003〉
International audience; BACKGROUND: Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries. Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are avail
Autor:
Annick Préfontaine, Quang Trinh Nguyen, Alain Fournier, Myriam Létourneau, François Harel, Jocelyn Dupuis, Yan Fu
Publikováno v:
Journal of Nuclear Medicine
Journal of Nuclear Medicine, Society of Nuclear Medicine, 2009, 50 (7), pp.1110-5. ⟨10.2967/jnumed.108.059428⟩
Journal of Nuclear Medicine, Society of Nuclear Medicine, 2009, 50 (7), pp.1110-5. ⟨10.2967/jnumed.108.059428⟩
This study was supported in part by the program of intellectual property management from the Canadian Institutes of Health Research, Ottawa, and by PulmoScience Inc., Montreal, Canada.; International audience; UNLABELLED: No test currently exists for
Autor:
Dana Darabi, Aram Ter Minassian, Florence Franconi, Laurent Lemaire, Jean-Jacques Le Jeune, Catherine Chapon, Jean-Pierre Benoit, Anne Pasco, Christine Caron
Publikováno v:
European Radiology
European Radiology, Springer Verlag, 2006, 16 (7), pp.1501-8. ⟨10.1007/s00330-005-0086-0⟩
European Radiology, 2006, 16 (7), pp.1501-8. ⟨10.1007/s00330-005-0086-0⟩
European Radiology, Springer Verlag, 2006, 16 (7), pp.1501-8. ⟨10.1007/s00330-005-0086-0⟩
European Radiology, 2006, 16 (7), pp.1501-8. ⟨10.1007/s00330-005-0086-0⟩
The distinction between intracellular (ICE) and extracellular edema (ECE) has a crucial prognostic and therapeutic importance in patients with severe traumatic brain injury (STBI). Indeed, ICE usually leads to cellular death, and maintenance of a cer
Autor:
Virginie Nerich, Sebastien Pili-Floury, Marielle Combe, Antoine Thiery-Vuillemin, Sylvain Onteniente, Damien Montange, Emmanuel Guardiola, Vincent Jullien, Bruno Chauffert, Patrice Muret, Xavier Pivot, Bernard Royer, Bruno Heyd, Delphine Delroeux, Jean-Pierre Kantelip, Sarah Piedoux, Elsa Kalbacher
Publikováno v:
BJC
BJC, 2012, 106 (3), pp.460-7. ⟨10.1038/bjc.2011.557⟩
BJC, 2012, 106 (3), pp.460-7. 〈10.1038/bjc.2011.557〉
British Journal of Cancer
BJC, 2012, 106 (3), pp.460-7. ⟨10.1038/bjc.2011.557⟩
BJC, 2012, 106 (3), pp.460-7. 〈10.1038/bjc.2011.557〉
British Journal of Cancer
International audience; BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a22637f52a6a99a835c536398e41bd1
https://www.hal.inserm.fr/inserm-00799502
https://www.hal.inserm.fr/inserm-00799502
Autor:
Khaled Benkali, Aurélie Prémaud, Pierre Marquet, Franck Saint-Marcoux, Lionel Rostaing, Jean-Baptiste Woillard, Annick Rousseau, Nassim Kamar, Saik Urien
Publikováno v:
Clinical Pharmacokinetics
Clinical Pharmacokinetics, Springer Verlag, 2010, 49 (10), pp.683-92. ⟨10.2165/11535950-000000000-00000⟩
Clinical Pharmacokinetics, Springer Verlag, 2010, 49 (10), pp.683-92. 〈10.2165/11535950-000000000-00000〉
Clinical Pharmacokinetics, 2010, 49 (10), pp.683-92. ⟨10.2165/11535950-000000000-00000⟩
Clinical Pharmacokinetics, Springer Verlag, 2010, 49 (10), pp.683-92. ⟨10.2165/11535950-000000000-00000⟩
Clinical Pharmacokinetics, Springer Verlag, 2010, 49 (10), pp.683-92. 〈10.2165/11535950-000000000-00000〉
Clinical Pharmacokinetics, 2010, 49 (10), pp.683-92. ⟨10.2165/11535950-000000000-00000⟩
International audience; BACKGROUND AND OBJECTIVES: Advagraf is a new extended-release once-daily formulation of tacrolimus, a potent immunosuppressant widely used in renal transplantation. The aims of his study were (i) to develop a population pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13cc1033accdd5685190044b9ac1c3e2
https://www.hal.inserm.fr/inserm-00926496
https://www.hal.inserm.fr/inserm-00926496
Autor:
Julie, Bertrand, Jean-Marc, Treluyer, Xavière, Panhard, Agnes, Tran, Solange, Auleley, Elisabeth, Rey, Dominique, Salmon-Céron, Xavier, Duval, France, Mentré, X, Panhard
Publikováno v:
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-678. ⟨10.1007/s00228-009-0660-5⟩
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-678. 〈10.1007/s00228-009-0660-5〉
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-78. ⟨10.1007/s00228-009-0660-5⟩
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-78. 〈10.1007/s00228-009-0660-5〉
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-678. ⟨10.1007/s00228-009-0660-5⟩
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-678. 〈10.1007/s00228-009-0660-5〉
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-78. ⟨10.1007/s00228-009-0660-5⟩
European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7), pp.667-78. 〈10.1007/s00228-009-0660-5〉
International audience; AIMS: To assess the relationship between genetic polymorphisms and indinavir pharmacokinetic variability and to study the link between concentrations and short-term response or metabolic safety. METHODS: Forty protease inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f823f741fa0ce8ce72e9aee66009971a
https://hal.archives-ouvertes.fr/hal-00534961/document
https://hal.archives-ouvertes.fr/hal-00534961/document
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2013, 72 (1), pp.167-80. ⟨10.1007/s00280-013-2182-1⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2013, 72 (1), pp.167-80. ⟨10.1007/s00280-013-2182-1⟩
Aflibercept (Zaltrap®) is a novel antiangiogenic agent that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-dependent tumor growth. We aimed to characterize the population pharmacokinetics (PK) of free and bound aflibercept in p
Autor:
Martine Reynaud-Gaubert, Romain Kessler, Marc Stern, Pierre Marquet, Caroline Monchaud, Annick Rousseau, Romain Guillemain, Christophe Pison, Brenda C. M. de Winter, Christiane Knoop, Marc Estenne
Publikováno v:
Clinical Pharmacokinetics
Clinical Pharmacokinetics, Springer Verlag, 2012, 51 (3), pp.175-86. ⟨10.2165/11594760-000000000-00000⟩
ResearcherID
Clinical Pharmacokinetics, Springer Verlag, 2012, 51 (3), pp.175-86. ⟨10.2165/11594760-000000000-00000⟩
ResearcherID
International audience; BACKGROUND: Therapeutic drug monitoring of tacrolimus is a major support to patient management and could help improve the outcome of lung transplant recipients, by minimizing the risk of rejections and infections. However, des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d3e13259b16b55500f13d7762787ae8
https://www.hal.inserm.fr/inserm-00925698
https://www.hal.inserm.fr/inserm-00925698
Publikováno v:
Handb Exp Pharmacol
Handb Exp Pharmacol, Vsevolod Gurevich, 2010, pp.19-48. ⟨10.1007/978-3-642-10324-7_2⟩
Handb Exp Pharmacol, Vsevolod Gurevich, 2010, pp.19-48. ⟨10.1007/978-3-642-10324-7_2⟩
International audience; Veterinary medicine faces the unique challenge of having to treat many types of domestic animal species, including mammals, birds, and fishes. Moreover, these species have evolved into genetically unique breeds having certain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a138868ae7a8e6cecd7d6f68b4467c55
https://hal.archives-ouvertes.fr/hal-00517529
https://hal.archives-ouvertes.fr/hal-00517529